# US 2017/0253930 A1 · Methods and compositions for inhibiting and treating neurological conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253930 A1
- Document ID: US20170253930A1
- Status: Published application
- Kind: A1
- Application number: 15/508,846
- Filed: 2015-09-04
- Published: 2017-09-07
- Earliest claimed: 2014-09-05
- Assignees: Population Bio, Inc.
- Applicants: Population Bio, Inc.
- Inventors: Eli HATCHWELL; Peggy EIS
- Web page: https://patentgrep.com/patent/US20170253930A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/015: carbocyclic
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/42: Phosphorus; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Q 2537/16: Assays for determining copy number or wherein the copy number is of special importance
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.

## Claims

### Claim 1

A method of diagnosing a susceptibility to a movement disorder such as Parkinson's Disease in a subject, comprising: providing nucleic acid sequence information from the subject on the presence or absence of at least genetic variation in one or more genes or regions in FIG. 8A or FIG. 8D; and diagnosing a susceptibility to the movement disoder in the subject if the subject has at least one genetic variation in the one or more genes or regions in FIG. 8A or FIG. 8D, wherein the at least genetic variation occurs in the gene or region more frequently in a population of subjects that have movement disorder than in a population of subjects that does not have movement disorder.

### Claim 2 (depends on 1)

The method of claim 1 further comprising assaying a nucleic acid sample of the subject thereby providing the nucleic acid sequence information.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2 wherein the at least one genetic variation is a copy number variation in a subregion in FIG. 9A or FIG. 9D.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3 wherein the sample is from blood, saliva, urine, serum, tears, skin, tissue, or hair.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4 wherein the sample comprises purified nucleic acid.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5 wherein the sample comprises amplified nucleic acid.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6 wherein a microarray analysis is employed to provide the nucleic acid sequence information.

### Claim 8 (depends on 7)

The method of claim 7 wherein the microarray analysis comprises a CGH array analysis or a SNP microarray analysis.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2 wherein the nucleic acid information is obtained by an amplification reaction, sequencing, Northern blots, or any combination thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9 wherein the diagnosis includes a neurological examination and/or medical history analysis of the subject.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10 wherein the nucleic acid sequence information or the at least one genetic variation is compared to those of subjects that do not have the movement disorder or are not suspected of having the movement disorder.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11 wherein the at least one genetic variation comprises one or more point mutations, SNPs, SNVs, polymorphisms, translocations, insertions, deletions, amplifications, inversions, microsatellites, interstitial deletions, copy number variations (CNVs), loss of heterozygosity, or any combination thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12 wherein the genetic variation comprises one or more CNVs that disrupt or modulate one or more genes listed in FIG. 10A, FIG. 10D, FIG. 11A or FIG. 11D.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13 wherein the at least one genetic variation comprises one or more CNVs that disrupt or modulate the expression or function of one or more RNA transcripts in FIG. 11A or FIG. 11D.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 to 14 wherein the nucleic acid sequencing information is obtained for the whole genome or whole exome from the one or more subjects.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15 wherein the nucleic acid sequencing information is obtained for the whole genome or whole exome from the one or more subjects and the nucleic acid information is obtained from in silico analysis.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16 wherein the subject is asymptomatic.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 to 17 wherein the genetic variation is in LYG1, LYG2, SUMF1, GNS/RASSF3, ARSB, GALNS, or PSAP.

### Claim 19

A method of screening a subject for a genetic variation that disrupts or modulates one or more genes in FIG. 10A or FIG. 10D, comprising: assaying a nucleic acid sample obtained from the subject for a genetic variation in one or more genes in FIG. 10A or FIG. 10D, wherein the genetic variation is associated with a neurological or movement disorder or an altered susceptibility to a neurological or movement disorder, and detecting genetic variations that disrupt or modulate the one or more genes.

### Claim 20 (depends on 19)

The method of claim 19 wherein the genetic variation is associated with Parkinson's Disease or an altered susceptibility to Parkinson's Disease (PD).

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20 wherein the genetic variation is in one of SEQ ID Nos:1 to 197 or 806 to 916 or sub-regions in FIG. 9A or FIG. 9D.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19 to 21 wherein the genetic variation comprises one or more point mutations, polymorphisms, translocations, insertions, deletions, amplifications, inversions, microsatellites, interstitial deletions, copy number variations (CNVs), single nucleotide polymorphisms (SNPs), single nucleotide variations (SNVs), or any combination thereof, wherein the genetic variation results in a loss of gene function or a gain of gene function of the one or more genes in FIG. 11A or FIG. 11D.

### Claim 23 (depends on 19)

The method of claim 19 wherein the genetic variation disrupts or modulates a genomic sequence encoded by any one of SEQ ID Nos 198-805, or an RNA transcript or polypeptide expressed therefrom.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method of any one of claims 19 to 23 wherein the assaying comprises detecting nucleic acid information from the nucleic acid sample by one or more methods selected from the group consisting of PCR, sequencing, a Northern blot, amplification, hybridization, microarray analysis, or any combination thereof.

### Claim 25 (depends on 24)

The method of claim 24 wherein the assaying is sequencing, and the sequencing comprises a sequencing method selected from the group consisting of Massively Parallel Signature Sequencing (MPSS), polony sequencing, 454 pyrosequencing, Illumina sequencing, SOLiD sequencing, ion semiconductor sequencing, DNA nanoball sequencing, heliscope single molecule sequencing, single molecule real time (SMRT) sequencing, RNAP sequencing, Nanopore DNA sequencing, sequencing by hybridization, or microfluidic Sanger sequencing.

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 19 to 25 wherein the nucleic acid sample is collected from blood, saliva, urine, serum, tears, skin, tissue, or hair from the subject.

### Claim 27 (depends on 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 19 to 26 wherein the assaying the nucleic acid sample from the subject comprises purifying polynucleotides from the nucleic acid sample; and directly assaying one or more of the purified polynucleotides, amplifying a nucleotide sequence of the purified polynucleotides, or performing a microarray analysis of the purified polynucleotides.

### Claim 28 (depends on 24)

The method of claim 24 wherein the assaying is microarray analysis, and wherein the microarray analysis comprises a Comparative Genomic Hybridization (CGH) array analysis or an SNP array analysis.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18 further comprising providing an evaluation of the subject's motor skills, autonomic function, neuropsychiatry, mood, cognition, behavior, thoughts, ability to sense, family history of early-onset neurological disorders or late-onset neurological disorders, or a combination thereof.

### Claim 30 (depends on 20)

The method of claim 20 further comprising selecting one or more therapies based on the presence of the genetic variation and administering the one or more therapies.

### Claim 31 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30)

The method of any one of claim 19 to 28 or 30 wherein the assaying the nucleic acid sample obtained from the subject comprises analyzing the whole genome or whole exome of the subject.

### Claim 32 (depends on 19, 20, 21, 22, 23, 30, 31)

The method of any one of claims 19 to 23 or 30 to 31 wherein nucleic acid information has already been obtained for the whole genome or whole exome of the subject and the nucleic acid information is obtained from in silico analysis.

### Claim 33 (depends on 19)

The method of claim 19 wherein the subject has at least one symptom of PD.

### Claim 34

A kit, array or panel for screening for a neurological disorder in subject, the kit, array or panel comprising reagents for assaying a nucleic acid sample from a subject for the presence of a genetic variation encoded by any one of SEQ ID Nos 1-197 or 806-916 or sub-regions thereof as set forth in FIG. 9A or FIG. 9D; wherein the genetic variation disrupts or modulates a genomic sequence encoded by SEQ ID Nos 198 to 805 or 908 to 1042, or an RNA transcript or polypeptide expressed therefrom.

### Claim 35

A method of preventing, inhibiting or treating a subject for a movement disorder such as Parkinson's Disease, comprising: providing nucleic acid sequence information from a subject at risk of, or having or suspected of having, the movement disorder including nucleic acid sequence information on one or more genes or regions in FIG. 8A or FIG. 8D; identifying in the subject at least one genetic variation in the one or more genes or regions; selecting an agent or a combination of agents that modulates the one or more genes or regions; and administering the selected agent or the selected combination of agents in an amount effective to prevent, slow the progression of, or treat one or more symptoms of the movement disorder in the subject.

### Claim 36 (depends on 35)

The method of claim 35 wherein the subject is heterozygous for at least one genetic variation in at least one gene that is associated with altered ubiquinone oxidoreductase activity or function, associated with lysozyme activity or function or associated with lysosomal metabolic activity or function.

### Claim 37 (depends on 35)

The method of claim 35 wherein the at least one genetic variation is in one or more genes or regions associated with LYG1, LYG2, HTR7, SUMF1, UNC13C, COMMD1, HIRA, PTPRT, SGCZ, CLTCL1, SLC25A1, ANKRD11, c5orf46, JAKMIP2, SCGB3A2, SPINK4, MYO1B, IQGAP2, DLGAP1 or DLGAP5.

### Claim 38 (depends on 35)

The method of claim 35 wherein the at least one genetic variation is in one or more genes or regions associated with SUMF1, GNS, ARSB, GALNS, or PSAP.

### Claim 39 (depends on 35)

The method of claim 35 wherein the at least one genetic variation is in one or more genes or regions associated with NQO1 or LYG.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The method of any one of claims 35 to 39 wherein the at least one genetic variation comprises one or more point mutations, polymorphisms, translocations, insertions, deletions, amplifications, inversions, microsatellites, interstitial deletions, CNVs, or loss of heterozygosity, or any combination thereof.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The method of any one of claims 35 to 40 wherein the agent or combination of agents includes an anti-oxidant, whey, a B vitamin, a carotene, a chloroacetic acid or a salt thereof, a dicarboxylic acid or a salt thereof, a vitamin K, a nucleoside, or a mineral.

### Claim 42 (depends on 41)

The method of claim 41 wherein the B vitamin includes vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B7, vitamin B9 or vitamin B12.

### Claim 43 (depends on 41)

The method of claim 41 wherein the anti-oxidant includes vitamin C, vitamin B, vitamin E, a co-factor, lipoic acid, carnitine, or an organosulfur compound.

### Claim 44 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 35 to 43 wherein the subject is further administered a dopamine agonist or a monoamine oxidase B inhibitor.

### Claim 45 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 35 to 44 wherein the subject is further administered an antibody, a genetic sequence, or a combination of genetic sequences.

### Claim 46 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 35 to 45 wherein the selected combination of agents comprises at least two anti-oxidants and a creatine compound.

### Claim 47 (depends on 46)

The method of claim 46 wherein one anti-oxidant is a co-factor, vitamin C or vitamin E.

### Claim 48 (depends on 46)

The method of claim 46 wherein one anti-oxidant is an organosulfur compound.

### Claim 49

A method of preventing, inhibiting or treating a symptom of a neurological disease in a subject, comprising: providing nucleic acid sequence information from a subject at risk of, or having or suspected of having, a neurological disease including nucleic acid sequence information on one or more genes or regions in FIG. 8B or FIG. 8C; identifying in the subject at least one genetic variation in the one or more genes or regions; and administering one or a combination of agents that includes a cofactor, whey, a B vitamin, a carotene, a chloroacetic acid or a salt thereof, a dicarboxylic acid or a salt thereof, a vitamin K, a nucleoside, a mineral, Butcher's broom (Ruscus aculeatus), curcumin, luteolin, epigallocatechin-3-gallate (antioxidant in white and green tea); thiamine, alcohol, low/no protein diets, protein supplements such as MSUD Express (manufactured by Vitaflo) that are free from branched chain amino acids leucine, isoleucine and valine, L-carnitine, salvianolic acid B, Momordica charantia (bitter melon), nicotinamide riboside, taurine, vitamin D, acetyl-L-carnitine, harpagoside, biotin, carnosine, aspirin, supplements containing antioxidants, vitamins, and other compounds such as B vitamins (B1, B2, B3, B5, B6, and/or B9), vitamin C, vitamin E, vitamin K, acetyl L-carnitine, alpha-lipoic acid, arginine, biotin, coenzyme Q10 (e.g., in the form of ubiquinol), creatine, glycerophosphocholine, glycine, nicotine adenine dinucleotide (NADH), omega-3 fatty acids (e.g., DHA), phosphatidylserine; high fat (ketogenic) diet, or inosine supplementation, in an amount effective to prevent, inhibit or treat at least one symptom of the neurological disease in the subject.

### Claim 50 (depends on 49)

The method of claim 49 wherein the co-factor comprises coenzyme Q10.

### Claim 51 (depends on 49)

The method of claim 49 wherein the mineral comprises magnesium, selenium, calcium or phosphorus.

### Claim 52 (depends on 49)

The method of claim 49 wherein the B vitamin comprises B1, or B2 or biotin.

### Claim 53 (depends on 49)

The method of claim 49 wherein the organosulfur compound comprises lipoic acid.

### Claim 54 (depends on 49)

The method of claim 49 wherein the carotene comprises beta-carotene.

### Claim 55 (depends on 49)

The method of claim 49 wherein the salt of the chloroacetic acid comprises sodium dichloroacetate or potassium dichloroacetate.

### Claim 56 (depends on 49)

The method of claim 49 wherein the salt of the dicarboxylic acid is sodium succinate.

### Claim 57 (depends on 49)

The method of claim 49 wherein the nucleoside comprises uridine.

### Claim 58 (depends on 49)

The method of claim 49 wherein a combination of said agents is administered.

### Claim 59 (depends on 35)

The method of claim 35 wherein the at least one genetic variation is in one or more genes or regions associated with ACE2, ACY3, ALDH2, ANKRD11, ARSB, BCL2LI, CA5B, CACNA1C, CALCRL_intergenic, CBR3, COMMD1, COX4I2, CSAD, CYP2R1, FXN, GALNS, GFRA3, GLRA3, GPR39, GRIA3, GRM1, GSTP1, HLCS, HTR7, KCNN2, LYG1, LYG2, NDUFAF2, NDUFC2-KCTD14, NDUFS4, NLRP3, NQO1, PDE3B, PIK3C3, PRCP, PRKAA1, PRKAG2, PSAP, S100A12, S100A7, S100A8, S100A9, SLC13A5, SMEK2, SMPD4, SRD5A2, STEAP1, SUMF1, SUPT3H, or TXN1P.

### Claim 60

A method of screening a subject for a genetic variation that disrupts or modulates one or more genes in any of FIG. 7, FIG. 11D or FIG. 12, comprising: assaying a nucleic acid sample obtained from the subject for a genetic variation in one or more genes in FIG. 7, FIG. 11D or FIG. 12, wherein the genetic variation is associated with a decreased susceptibility to developing a neurological or movement disorder or symptoms associated with the disorder.

### Claim 61 (depends on 60)

The method of claim 60 wherein the gene comprises CITED4, CTPS1 or MSRI.
